Klaus Grohe Prize 2022

Klaus Grohe Prize 2022

Author: ChemistryViews

Raphaël Rodriguez, Institut Curie, Paris, France, has received the Klaus Grohe Prize 2022 from the Klaus Grohe Foundation, which is part of the German Chemical Society (GDCh). The prize is awarded to scientists who have performed excellent work in researching new principles of drug research and whose research results make an important contribution to application. The prize is endowed with EUR 50,000. The award was presented at the International Symposium on Medicinal Chemistry in Nice, France, on September 4, 2022.

Rodriguez receives the award for his pioneering work at the interface between chemistry and biology, combining preparative organic synthesis with molecular and cell biology. For example, he contributed to the development of remodelin, a small molecule that can repair defects in laminopathy cells (which are related to rare genetic disorders) and improve cellular fitness by reducing endogenous levels of DNA damage. He also performed the first chemical syntheses of the complex natural product marmycin and the drug ironomycin, which targets iron metabolism. With his research group, he also elucidated the mechanism of action of salinomycin against cancer stem cells and identified the role of iron in maintaining these cells.

Raphaël Rodriguez was born in Avignon, France, in 1978. He studied chemistry at the Universities of Avignon and Marseille, France. He received his Ph.D. in organic chemistry from the University of Oxford, UK, and the University of Marseille. In 2005, he moved to the University of Cambridge, UK, as a postdoctoral researcher, before joining the CNRS (Centre national de la recherche scientifique) in Paris, France, as a group leader in 2012. There, he was appointed Research Director at the Institut Curie in 2017.

Among other honors, Rodriguez has received the Tetrahedron Young Investigator Award, the Prix Lacassagne from the Collège de France, and the Grand Prix Charles Defforey from the Académie des Sciences, all in 2019. He is a scientific co-founder of several companies, including SideROS and Adrestia Therapeutics.

Selected Publications


Leave a Reply

Kindly review our community guidelines before leaving a comment.

Your email address will not be published. Required fields are marked *